Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. 2003

Erwan Bézard, and Sandrine Ferry, and Ulrich Mach, and Holger Stark, and Ludovic Leriche, and Thomas Boraud, and Christian Gross, and Pierre Sokoloff
Basal Gang, Laboratoire de Neurophysiologie, CNRS UMR 5543, Université Victor Segalen, 33076 Bordeaux, France. erwan.bezard@umr5543.u-bordeaux2.fr

In monkeys rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), expression of the dopamine D3 receptor was decreased. However, levodopa-induced dyskinesia (LID), similar to the debilitating and pharmacoresistant involuntary movements elicited after long-term treatment with levodopa in patients with Parkinson disease (PD), was associated with overexpression of this receptor. Administration of a D3 receptor-selective partial agonist strongly attenuated levodopa-induced dyskinesia, but left unaffected the therapeutic effect of levodopa. In contrast, attenuation of dyskinesia by D3 receptor antagonists was accompanied by the reappearance of PD-like symptoms. These results indicated that the D3 receptor participated in both dyskinesia and the therapeutic action of levodopa, and that partial agonists may normalize D3 receptor function and correct side effects of levodopa therapy in patients with PD.

UI MeSH Term Description Entries
D007546 Isoquinolines A group of compounds with the heterocyclic ring structure of benzo(c)pyridine. The ring structure is characteristic of the group of opium alkaloids such as papaverine. (From Stedman, 25th ed)
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D009043 Motor Activity Body movements of a human or an animal as a behavioral phenomenon. Activities, Motor,Activity, Motor,Motor Activities
D009281 Naphthalenes Two-ring crystalline hydrocarbons isolated from coal tar. They are used as intermediates in chemical synthesis, as insect repellents, fungicides, lubricants, preservatives, and, formerly, as topical antiseptics.
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011759 Pyrrolidines Compounds also known as tetrahydropyridines with general molecular formula (CH2)4NH. Tetrahydropyridine,Tetrahydropyridines
D004409 Dyskinesia, Drug-Induced Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199) Dyskinesia, Medication-Induced,Medication-Induced Dyskinesia,Drug-Induced Dyskinesia,Drug-Induced Dyskinesias,Dyskinesia, Drug Induced,Dyskinesia, Medication Induced,Dyskinesias, Drug-Induced,Dyskinesias, Medication-Induced,Medication Induced Dyskinesia,Medication-Induced Dyskinesias
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000178 Acrylamides Colorless, odorless crystals that are used extensively in research laboratories for the preparation of polyacrylamide gels for electrophoresis and in organic synthesis, and polymerization. Some of its polymers are used in sewage and wastewater treatment, permanent press fabrics, and as soil conditioning agents.

Related Publications

Erwan Bézard, and Sandrine Ferry, and Ulrich Mach, and Holger Stark, and Ludovic Leriche, and Thomas Boraud, and Christian Gross, and Pierre Sokoloff
July 2003, The Lancet. Neurology,
Erwan Bézard, and Sandrine Ferry, and Ulrich Mach, and Holger Stark, and Ludovic Leriche, and Thomas Boraud, and Christian Gross, and Pierre Sokoloff
June 2005, Parkinsonism & related disorders,
Erwan Bézard, and Sandrine Ferry, and Ulrich Mach, and Holger Stark, and Ludovic Leriche, and Thomas Boraud, and Christian Gross, and Pierre Sokoloff
January 2005, Annals of neurology,
Erwan Bézard, and Sandrine Ferry, and Ulrich Mach, and Holger Stark, and Ludovic Leriche, and Thomas Boraud, and Christian Gross, and Pierre Sokoloff
January 2022, Experimental neurology,
Erwan Bézard, and Sandrine Ferry, and Ulrich Mach, and Holger Stark, and Ludovic Leriche, and Thomas Boraud, and Christian Gross, and Pierre Sokoloff
March 2024, Neuroscience letters,
Erwan Bézard, and Sandrine Ferry, and Ulrich Mach, and Holger Stark, and Ludovic Leriche, and Thomas Boraud, and Christian Gross, and Pierre Sokoloff
January 2000, European archives of psychiatry and clinical neuroscience,
Erwan Bézard, and Sandrine Ferry, and Ulrich Mach, and Holger Stark, and Ludovic Leriche, and Thomas Boraud, and Christian Gross, and Pierre Sokoloff
January 2017, Cerebral cortex (New York, N.Y. : 1991),
Erwan Bézard, and Sandrine Ferry, and Ulrich Mach, and Holger Stark, and Ludovic Leriche, and Thomas Boraud, and Christian Gross, and Pierre Sokoloff
March 2021, Biomedicines,
Erwan Bézard, and Sandrine Ferry, and Ulrich Mach, and Holger Stark, and Ludovic Leriche, and Thomas Boraud, and Christian Gross, and Pierre Sokoloff
January 1977, Transactions of the American Neurological Association,
Erwan Bézard, and Sandrine Ferry, and Ulrich Mach, and Holger Stark, and Ludovic Leriche, and Thomas Boraud, and Christian Gross, and Pierre Sokoloff
May 1971, Lancet (London, England),
Copied contents to your clipboard!